explore -WSS

explore

author：leisure time 2025-09-07 11:13:16 - browse：89543

Pfizer on Friday said it was stopping development of a twice-daily oral obesity medication after an underwhelming clinical trial, a blow to the company’s efforts to compete in the booming field of weight-loss medications.

The medicine, danuglipron, met its primary target in a placebo-controlled Phase 2b trial, leading to a statistically significant amount of weight lost, the company said. But the weight reductions were smaller than those seen in trials of rival medicines targeting the same GLP-1 pathway, and a high rate of patients experienced side effects and dropped out of the trial.

Pfizer said it would not move twice-daily danuglipron into Phase 3 trials, but that instead it would focus on a once-daily formulation, which is currently undergoing pharmacokinetic studies. Data are expected in the first half of 2024.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： Medicare Advantage plans can’t deny care with AI, CMS warns

focus

WSS

Novo Holdings to buy drug manufacturer Catalent in $16.5B deal

ReNAgade cuts staff seven months after raising $300 million

CDC director unscathed in first congressional testimony

UnitedHealth has 90,000 doctors — 10% of all physicians in U.S.

The CDC's new social media misinformation war

Texas Medical Board asked to define abortion emergency exception

focus

explore

knowledge

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Readout LOUD: Venture capital, Gilead, and more M&A

Malaria cases in Florida and Texas: Here’s what you need to know

The Biogen Aduhelm mess could happen again

Virginia high school admissions case could be legal follow

Fetal surgery at risk from Dobbs and new abortion restrictions

DIEP, the 'gold standard' of breast reconstruction, is under threat

Why Novartis is going to walk from its acquisition of MorphoSys

Medical records are filled with copy

UnitedHealth has 90,000 doctors — 10% of all physicians in U.S.

knowledge

Johnson & Johnson sued for allegedly overpaying for workers' drugs

Why Novartis is going to walk from its acquisition of MorphoSys

Why Novartis is going to walk from its acquisition of MorphoSys

Saudi VC loops Novo Nordisk, biotech VCs into longevity incubator

340B reform proposal comes out of Senate working group

Readout Newsletter: The latest in Pfizer, Moderna, and Sanofi

explore

focus

focus

hotspot